Enanta has discovered novel protease inhibitors for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enanta’s collaboration with AbbVie, include glecaprevir and paritaprevir.

AbbVie is responsible for all worldwide commercialization of paritaprevir-containing and glecaprevir-containing treatment regimens for HCV.

Paritaprevir, THE INITIAL Protease Inhibitor for HCV Infection

Paritaprevir is an NS3/4A protease inhibitor discovered during the ongoing collaboration between Enanta and AbbVie for HCV protease inhibitors and the first developed in AbbVie’s treatment regimens that include protease inhibitors.

Paritaprevir is one of the direct-acting-antivirals in VIEKIRA PAK and the other treatment regimens that AbbVie developed and has been marketing worldwide for HCV genotypes 1 and 4.

Glecaprevir, Enanta’s Second HCV Protease Inhibitor

Glecaprevir is the second protease inhibitor discovered within the Enanta-AbbVie collaboration.

Glecaprevir was designed to enable once-daily dosing without ritonavir or ribavirin. AbbVie has co-formulated it in a fixed-dose combination with AbbVie’s new NS5A inhibitor, pibrentasvir. The U.S. Food and Drug Administration has approved MAVYRET™ (glecaprevir/pibrentasvir) and the European Commission has granted AbbVie Marketing Authorization for MAVIRET™ (glecaprevir/pibrentasvir) in the E.U. MAVIRET™ (glecaprevir/pibrentasvir) has also been approved by the Japanese Ministry of Health, Labour and Welfare.

For an overview of our research, including our licensed products, please see Our Pipeline.